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Abstract
This study aimed to investigate the virological status in liver (both tumor and adjacent non-tumor tissue), the clinical
features and the contribution of occult HBV infection (OBI) to postoperative prognosis in HBeAg-negative(2) hepatocellular
carcinoma (HCC) patients in China. Using quantitative TaqMan fluorescent real-time PCR assays, HBV covalently closed
circular DNA (cccDNA) and total DNA (tDNA) were both quantified in 11 (HBsAg(2)) and 57 (HBsAg-positive(+)) pairs of
tumor tissue (TT) and adjacent non-tumor tissue (ANTT) obtained from HBeAg(2) HCC patients who received no antiviral
treatment and were negative for anti-HCV before surgical treatment. Of 11 HBsAg(2) patients, 36% were with HBsAb(+)
HBeAb(+) HBcAb(+). However, only 9% of the HBsAg(2) patients were HBsAb(2) HBeAb(+) HBcAb(+), which accounted for
the majority (93%) in the HBsAg(+) group. TT and ANTT HBV tDNAs in 11 HCC patients with HBsAg (2) and HBeAg (2) were
all detectable. HBV cccDNA and tDNA were all lower in the HBsAg(2) group than those in the HBsAg(+) group. By Kaplan-
Meier analysis, patients with OBI were associated with a lower risk of cirrhosis and better overall survival (OS). The
intracellular HBV DNAs, such as HBV cccDNA and tDNA are valuable biological markers for the diagnosis of occult HBV
infection in HCC patients. This would assist the clinical implementation of a more personalized therapy for viral re-activation
control and improve the survival rate of OBI patients.
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Introduction
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer death worldwide [1,2]. The major risk factor for
the development of HCC is hepatitis B virus (HBV) infection [3,4].
A peculiar aspect of chronic HBV infection is the persistence of
HBV genomes in the absence of serum HBs antigen (HBsAg), so
called ‘occult’ infection. The geographic distribution of occult
HBV infection (OBI) is associated with the prevalence of HBV
infection and its prevalence is high in HCC populations [5].
OBI can occur not only in individuals with anti-HBs and/or
anti-HBc antibodies but also in those who are negative for HBV
markers [5,6]. The seronegativity in these OBI patients may be
caused by naturally occurring mutants of HBV, which alters either
the immunoreactivity of various HBV proteins or the quantity of
serum HBsAg [7]. The individuals with OBI usually exhibit lower
levels of viremia [8]. A decrease in HBV viral load as well as
replication and various relevant mutations have been implicated in
the explanation of HBsAg-negative (2) [9]. Several previous
studies have reported the existence of HBV DNA in liver tissues of
HBsAg-negative patients [10,11,12,13] and the OBI significantly
correlated with cirrhosis in chronic hepatitis C virus (HCV)
carriers [14,15,16]. OBI is a worldwide diffused entity, evidence
showed that this condition might be potentially oncogenetic
[5,17]. However, in those HCC patients with HBsAg and HBeAg
negative, the virologic status and the clinical features of OBI are
still not thoroughly studied.
HBV covalently closed circular DNA (cccDNA) is an important
intermediate in the life cycle of HBV, from which the HBV
pregenomic RNA and all HBV messenger RNA transcripts
originate [13]. Although the level of HBV replication in those
HCC patients with HBsAg and HBeAg negative is low, little is
known about the level of HBV covalently closed circular DNA
(cccDNA) and total DNA (tDNA) in paired tumor tissues (TT) and
adjacent non-tumor tissues (ANTT) in chronic Hepatitits B (CHB)
endemic areas, such as China.
We therefore conducted a prospective study. The primary aim
was to investigate the virologic status in the liver (both TT and
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ANTT) among these HCC patients with HBsAg (2) and HBeAg
(2). The second aim was to determine the clinical features and the
contribution of occult HBV infection (OBI) to postoperative
prognosis for HCC patients with HBsAg (2) and HBeAg (2) in
China.
Materials and Methods
Patients and samples
This study included a HBsAg-negative group (n = 11) and a
HBsAg-positive (+) group (n= 57) of HCC patients with HBeAg
(2) (between March 2007 and May 2009) who received no
antiviral treatment and were negative for anti-HCV before
surgical resection at the Shanghai Eastern Hepatobiliary Surgery
Hospital (EHBH) in Shanghai, China. The study was approved by
the Chinese Ethics Committee of Human Resources at the Second
Military Medical University. All study participants provided
written informed consent.
The inclusion criteria were patients with no evidence of
hepatitis C virus (HCV) or hepatitis D virus (HDV) co-infection;
no previous antiviral treatment; complete resection of tumor with
sufficient safety margin (R0) and histologically proven HCC.
1) The HBsAg-negative group: HBsAg-negative and
HBeAg-negative for at least 6 months, undetectable
serum HBV DNA.
2) The HBsAg-positive group: HBsAg-positive and HBeAg-
negative for at least 6 months.
The exclusion criteria included a history of liver transplantation
and other malignancies, tumors of uncertain origin, metastatic
liver cancer, autoimmune liver diseases, drug-related liver diseases,
alcoholic hepatitis and other causes of chronic liver diseases (such
as HCV, HDV, HEV, HIV) diagnosed before enrollment.
Details of patient clinical diagnosis, follow up are included in
File S1.
Quantitation of HBV cccDNA and total DNA (tDNA) in
tissues
Viral DNAs in frozen tissues were extracted using the QIAamp
DNA Mini kit (QIAGEN GmbH, Hilden, Germany). HBV
cccDNA and tDNA were detected using real-time polymerase
chain reaction (PCR) with TaqMan fluorescent probes (Fosun
Diagnostics, Shanghai, China) according to the method described
by Bettina et al. with a slight modification [18]. The extracted
DNA samples were treated with plasmid DNA-safe ATP-
dependent enzyme (Epicentre, Madison, WI). Real-time PCR
was performed on an ABI 7500 (Life Technologies Corporation,
Foster City, CA) using a 50 ml reaction volume containing 20 ng
of DNA (for cccDNA quantification, a volume equivalent to 20 ng
prior to DNase treatment), 2.5 mM MgCl2, 0.5 mM of forward
and reverse primers, and a 0.4 mM probe. Forward and reverse
primers were F1 and R1 for cccDNA amplification, respectively
and F2 and R2 for total intrahepatic HBV DNA amplification,
respectively. TaqMan probes were TaqP1 for cccDNA quantifi-
cation and TaqP2 (Table S1) for total intrahepatic HBV DNA
quantification. GAPDH, a single copy housekeeping gene present
in human was used in the real-time PCR as a control to estimate
the number of cells represented in each PCR reaction. Serial
dilutions of genomic DNAs were used as standards to quantitate
GAPDH DNA from liver tissues. The results of cccDNA and
tDNA were normalized to copies/106 cells.
Statistical analysis
All statistical analyses were two sided and performed using SPSS
17.0 for Windows (SPSS Inc., Chicago, IL). A P value of ,0.05
was considered as statistically significant. Details are included in
File S1.
Results
Immunological characteristics of HCC patients
The immunological characteristics of HBeAg(2) HCC patients
are summarized in Table 1. There was significant difference
between the HBsAg(2) and the HBsAg(+) group (P,0.001). Of 11
patients in the HBsAg(2) group, 36% were with HBsAb (+)
HBeAb (+) HBcAb (+). The patients with HBsAb (+) HBeAb (2)
HBcAb (+), HBsAb (2) HBeAb (2) HBcAb (+) and HBsAb (2)
HBeAb (2) HBcAb (2) respectively accounted for 18%. However,
the percentage of patients with HBsAb (2) HBeAb (+) HBcAb (+)
is significantly higher in HBsAg (+) group than in HBsAg (2) one.
In the HBsAg(2) group, there were 6 HBsAb(+) patients (54%)
and 5 HBsAb(2) patients (46%), 5 HBeAb(+) patients (46%) and 6
HBeAb(2) patients (54%), and 9 HBcAb(+) patients (82%) and 2
HBcAb(2) patients (18%). However, in the HBsAg(+) group, there
were only 1 patients (2%) with HBsAb(+) and 56 patients (98%)
with HBsAb(2),54 patients (95%) with HBeAb(+) and 3 patients
(5%) with HBeAb(2), and 57 patients (100%) with HBcAb(+).
Intrahepatic HBV DNAs in 11 HCC patients with HBsAg
(2) and HBeAg (2) were all detectable
The paired TT/ANTT of HCC patients with HBeAg (2) were
stratified into different group (A–E) according to the immunolog-
ical characteristics, and examined for intracellular HBV cccDNA
and tDNA levels (Table 2). Interestingly, in the HBsAg(2) group,
all HBV tDNAs were detectable, and 3 TT and 5 ANTT
cccDNAs were undetectable. Among the HBsAg(+) group,
Table 1. Immunological characteristics of HBeAg-negative HCC patients.
Characteristic HBsAg (2) and HBeAg (2) HBsAg (+) and HBeAg (2) P value
No. of patients (%) No. of patients (%)
HBsAb (+) HBeAb (+) HBcAb (+) 4 (36%) 1 (2%) P,0.001
HBsAb (+) HBeAb (2) HBcAb (+) 2 (18%) 0
HBsAb (2) HBeAb (+) HBcAb (+) 1 (9%) 53 (93%)
HBsAb (2) HBeAb (2) HBcAb (+) 2 (18%) 3 (5%)
HBsAb (2) HBeAb (2) HBcAb (2) 2 (18%) 0
Total 11 57
doi:10.1371/journal.pone.0107162.t001
Intracellular HBV DNAs in HCC Patients with HBsAg and HBeAg Negative
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e107162
T
a
b
le
2
.
Q
u
an
ti
fi
ca
ti
o
n
o
f
in
tr
ah
e
p
at
ic
H
B
V
D
N
A
s
in
H
C
C
p
at
ie
n
ts
.
C
h
a
ra
ct
e
ri
st
ic
G
ro
u
p
H
B
sA
b
H
B
e
A
b
H
B
cA
b
N
o
.
o
f
p
a
ti
e
n
ts
(%
)
T
T
(l
o
g
1
0
co
p
ie
s/
1
0
6
ce
ll
s)
A
N
T
T
(l
o
g
1
0
co
p
ie
s/
1
0
6
ce
ll
s)
T
T
ra
ti
o
(%
)
A
N
T
T
ra
ti
o
(%
)
cc
cD
N
A
H
B
V
tD
N
A
cc
cD
N
A
H
B
V
tD
N
A
H
B
sA
g
(2
)
an
d
H
B
e
A
g
(2
)
A
+
+
+
4
(3
6
%
)
3
.0
5
6
0
.5
3
4
.7
8
6
1
.6
5
3
.2
9
6
0
.6
6
*
4
.8
3
6
2
.0
3
1
1
.9
6
6
1
7
.0
9
0
.5
6
6
0
.6
7
B
+
2
+
2
(1
8
%
)
2
.3
3
6
0
.0
1
5
.6
2
6
0
.1
6
2
.6
7
6
0
.5
6
6
.0
7
6
0
.5
5
0
.0
5
6
0
.0
2
0
.0
4
6
0
.0
1
C
2
+
+
1
(9
%
)
1
.4
5
5
.5
9
u
n
d
e
te
ct
ab
le
1
.6
4
0
.0
1
u
n
d
e
te
ct
ab
le
D
2
2
+
2
(1
8
%
)
6
.0
7
*
5
.2
2
6
5
.0
6
u
n
d
e
te
ct
ab
le
2
.5
4
6
0
.1
5
0
.1
9
*
u
n
d
e
te
ct
ab
le
E
2
2
2
2
(1
8
%
)
u
n
d
e
te
ct
ab
le
2
.6
5
6
0
.0
1
4
.8
6
*
4
.8
1
6
2
.9
5
u
n
d
e
te
ct
ab
le
0
.9
2
*
T
o
ta
l
1
1
(1
0
0
%
)
H
B
sA
g
(+
)
an
d
H
B
e
A
g
(2
)
A
+
+
+
1
(2
%
)
3
.8
2
5
.1
7
3
.7
5
6
.8
3
4
.4
5
0
.0
8
B
+
2
+
0
C
2
+
+
5
3
(9
3
%
)
4
.5
7
6
1
.6
7
6
.6
2
6
1
.4
2
4
.8
6
6
1
.1
6
6
.9
5
6
0
.8
8
2
.7
3
6
4
.4
5
1
.9
7
6
2
.7
6
D
2
2
+
3
(5
%
)
6
.9
9
6
0
.0
7
*
6
.4
3
6
3
.5
4
4
.7
0
6
1
.4
3
6
.6
1
6
0
.6
1
4
.7
4
6
4
.7
1
*
2
.8
0
6
3
.3
4
E
2
2
2
0
T
o
ta
l
5
7
(1
0
0
%
)
A
b
b
re
vi
at
io
n
s:
H
B
V
,
h
e
p
at
it
is
B
vi
ru
s;
cc
cD
N
A
,
co
va
le
n
tl
y
cl
o
se
d
ci
rc
u
la
r
D
N
A
;
tD
N
A
,
to
ta
l
D
N
A
;
T
T
,
tu
m
o
r
ti
ss
u
e
;
A
N
T
T
,
ad
ja
ce
n
t
n
o
n
-t
u
m
o
r
ti
ss
u
e
.
‘‘+
’’
an
d
‘‘2
’’
in
d
ic
at
e
p
o
si
ti
ve
an
d
n
e
g
at
iv
e
d
e
te
ct
io
n
.
*
in
d
ic
at
e
th
e
co
n
ce
n
tr
at
io
n
o
f
o
n
e
sa
m
p
le
w
as
u
n
d
e
te
ct
ab
le
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
7
1
6
2
.t
0
0
2
Intracellular HBV DNAs in HCC Patients with HBsAg and HBeAg Negative
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e107162
cccDNA was undetectable in one TT sample. The relationship
between serum HBV DNA and cccDNA were shown in Table S2.
Both the TT and the ANTT cccDNA made up a smaller portion
of the tDNA in the HBsAg(2) group than those in the HBsAg(+)
group, other than those patients with HBsAb (+) HBeAb (+)
HBcAb (+).
The difference in TT/ANTT HBV cccDNA and tDNA
between the HBsAg(2) group and the HBsAg(+) one were shown
in Figure 1. The HBV cccDNA was significantly lower in the
HBsAg(2) group than in the HBsAg(+) group (TT: 3.0561.39 vs.
4.6461.69 log10 copies/10
6 cells, P=0.013; ANTT: 3.3560.94
vs. 4.8361.16 log10 copies/10
6 cells, P=0.004). Similarly, the
HBV tDNA was also significantly lower in the HBsAg(2) group
than in the HBsAg(+) group (TT: 4.7062.13 vs. 6.5961.53 log10
copies/106 cells, P=0.001; ANTT: 4.3462.06 vs. 6.9360.86
log10 copies/10
6 cells, P=0.002). However, no statistical signif-
icant difference in TT/ANTT ratios was observed between the
HBsAg(2) and the HBsAg(+) group (TT: 6.02612.87 vs.
2.8364.40%, P=0.509; ANTT: 0.4560.55 vs. 1.9862.75%,
P=0.180).
Occult HBV infection was associated with a lower risk of
cirrhosis and better overall survival
Eleven Patients with occult HBV infection had higher albumin
(ALB), well-differentiated tumors (E-S grades I and II) and a lower
risk to develop cirrhosis (Table 3). However, the other demo-
graphic and clinicopathologic characteristics were not significantly
different between the two groups.
By Kaplan-Meier analysis, although patients with OBI did not
differ significantly in overall survival (OS) and disease-free survival
(DFS) (P=0.173 and P=0.386, Fig. 2A, 2B), patients with OBI
showed lower mortality rates at 1-, 2- and 3-years after resection.
Discussion
HCC is one of the most common cancers worldwide, and its
incidence appears to be increasing [1,16]. Most cases of
hepatocellular carcinoma (80%) arise in eastern Asia and sub-
Saharan Africa, where chronic infection with HBV is the
dominant risk factor [1]. However, this malignancy is not only
mainly related to an overt (HBsAg positive) HBV infection, but
also linked with occult HBV infection (HBsAg negative) [5]. The
long-lasting persistence of HBV genomes in the liver (with
detectable or undetectable HBV DNA in the serum of individuals
testing negative for HBsAg) is termed OBI [17]. Our study based
on the quantitative TaqMan fluorescent real-time PCR assay
provides valuable information on the clinical and virological
features of HCC patients with both HBsAg and HBeAg negative.
In our study, HBV tDNAs in 11 HCC patients with HBsAg(2)
and HBeAg(2) were all detectable in TT or ANTT at the time of
surgical resection. There were approximately half of these patients
with HBsAb(+) (54%) and with HBeAb(+) (46%), and 82% of
patients with HBcAb(+) in the HBsAg(2) and HBeAg(2) group.
We confirmed that HBV could persist in liver after the
disappearance of HBsAg in individuals with previous exposure
to the virus, retaining the serological footprint of HBcAb positivity
with such a virologic status [19]. But there were 2 cases with all
serological markers negative (HBsAg, HBeAg, HBsAb, HBeAb
and HBcAb), in which had detectable HBV tDNA in TT/ANTT.
Previous studies have revealed that the HCC patients with OBI
who are HBsAg-negative but positive for HBcAb are at risk of
HBV reactivation after undergoing chemotherapy or immuno-
suppressive therapy [20,21,22]. Thus, it is very important to
monitor HBV DNA levels regularly to achieve the early
administration of antiviral or antineoplastic drugs before the onset
of ALT elevation, however, the optimum testing frequency and
noninvasive detection technology of HBV DNA in occult HBV
carriers will need additional study.
To clarify the virological characteristics of HBV, we detected
the cccDNA levels in cancerous tissues and non-cancerous tissues.
cccDNA does not take part in replication directly, because it is
maintained as a stable pool inside the hepatocyte nuclei [23]. We
found that the levels of cccDNA and tDNA in cancerous tissues
and non-cancerous tissues were significantly lower in the
HBsAg(2) group than in the HBsAg(+) group. Both TT and
ANTT cccDNA made up a smaller portion of the tDNA in the
HBsAg-negative group, other than the tumor tissue ratio in the
type of HBsAb (+) HBeAb (+) HBcAb (+). It is likely that OBI
reactivates with the development of an immunosuppressive status.
Although the cause of OBI reactivation is yet to be understood,
it is necessary to consider the following factors: the host’s immune
surveillance, restored virus, the impact of liver cancer cells and
coinfection of other types of HBV. (1) Virus factors: In most cases
there is no change in the a determinant that could explain the lack
of HBsAg detection [24,25,26]. Although in a few cases (10%) the
lack of HBsAg detection is due to infection with mutated viruses
unrecognized by available assays (S-escape mutants) [27,28,29],
the typical OBI is related to strongly suppressed HBV replication
and the cause of HBV suppression is yet to be understood [17].
(2) Host factors: The genetic differences between individuals can
lead to different immunological environment. An in vitro study
showed that occult viral isolates could fully restore replication,
transcription, and protein synthesis abilities once the viruses are
taken out of the host liver microenvironment [30]. However, the
association between host genomic variation and virus replication
suppression needs to be investigated. (3) Coinfection. Because the
exclusion criteria in our study included a history of other causes of
chronic liver diseases (such as HCV, HDV, HEV, HIV) diagnosed
before enrollment, there is no evidence of direct effects of infection
of other types of HBV. Further studies are required to determine
the characteristics of the reactivated viruses in HBsAg and HBeAg
negative but HBsAb(+), HBeAb(+) and HBcAb(+) occult HBV
carriers.
In this study, we found that patients with occult HBV infection
are less likely to develop cirrhosis and had better overall survival.
This observation strongly supported the possible contribution of
OBI to the establishment of cirrhosis and the possible direct or
indirect role in the development of HCC. In patients with
diagnosable/detectable low-grade HBV replication, the virus
retains its pro-oncogenic properties [31] [17]. Therefore, the
Figure 1. TT/ANTT tDNA and cccDNA are associated with
HBsAg status in HBeAg (2) patients.
doi:10.1371/journal.pone.0107162.g001
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mechanisms leading to HCC in occult HBV carriers seem to be
similar to those in overt cases.
Our study has limitations. Firstly, samples were from a single
department and the size was limited. In future studies, larger
sample size would be preferred in order to validate the findings
shown in this study. Besides, studies should continue to function-
ally characterize viral mutations and the relevant viral genes.
In summary, our findings suggest that the intracellular HBV
DNAs, such as HBV cccDNA and tDNA are valuable biological
markers for the diagnosis of occult HBV infection in HCC
patitents. This would assist the clinical implementation of a more
personalized therapy for viral re-activation control and improve
the survival rate of OBI patients.
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